BioCentury
ARTICLE | Financial News

Cyteir raises $29M series B

March 8, 2018 7:51 PM UTC

Cyteir Therapeutics Inc. (Cambridge, Mass.) raised $29 million in a series B round led by Venrock. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures.

Cyteir plans to begin clinical studies next year of its small molecule inhibitors of RAD51 homolog (RAD51) in cancer indications. ...

BCIQ Company Profiles

Cyteir Therapeutics Inc.